MiMedx appoints Joseph Capper as CEO
30 Jan 2023
Executive Change
He replaces interim CEO Todd Newton, who was appointed in September 2022. Newton will remain in his role on the Board of Directors.
Capper has nearly 30 years of medtech and life sciences experience. He most recently was CEO of BioTelemetry, which Royal Philips acquired for $2.8 billion. Before that, Capper was president and CEO of both Home Diagnostics and CCS Medical. He has held numerous leadership roles at Bayer as well.
“We are thrilled to welcome Joe to MiMedx as the new CEO,” Kathleen Behrens, chair of the board, said in a news release. “Over the past several months, the search committee has conducted an evaluation of very strong candidates for this role. Our focus has been to find an experienced executive with a track record of delivering results who shares in our enthusiasm for the future of this Company. In Joe, we believe we have found a proven and dynamic leader that combines a wealth of experience in medtech and a track record of numerous value-creating achievements over the course of his career. Joe has demonstrated the ability to lead large organizations, drive sustained growth and clearly understands how to maximize the value of an organization.”
With the new CEO appointment, the company’s board of directors has increased to nine members.
“I am extremely excited for the opportunity to lead MiMedx at this pivotal juncture in the company’s evolution,” Capper said. “I was attracted to MiMex as it possesses key components which are essential for future success: market-leading technology, a rich product pipeline, an experienced commercial leadership team and a strong financial profile. There is a growing need from clinicians and patients for better solutions to aid in the healing process. With the right strategic focus, targeted investments, and a culture of execution, I am confident MiMedx will be poised for significant growth. I believe there will be no shortage of opportunities for us to expand and profitably scale this business. I look forward to applying my decades of experience to improve patient care and to maximize the full potential of MiMedx.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.